EuropeThe vaccine ‘triggered the production of adequate amounts of antibodies against both viruses,’ the agency said.Moderna’s headquarters in Cambridge, Mass., on May 8, 2020. Maddie Meyer/Getty ImagesZachary StieberSenior Reporter2/27/2026|Updated: 2/27/20260:00Europe’s medical regulator on Feb. 27 recommended approval of Moderna’s COVID-19-influenza vaccine.Data show the vaccine, known as mCombriax, “triggered the production of adequate amounts of antibodies against both viruses,” the European Medicines Agency said in a statement.
European Regulator Recommends Approving Modernas COVID-Flu Vaccine
Date:
